[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494247":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":34,"responsibleParty":55,"collaborators":59,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":36,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":25,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Xinjiang Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Renal denervation and maintenance of heart failure medications","EXPERIMENTAL","Renal denervation in patients with HFpEF and uncontrolled hypertension",[13],"Procedure: Renal denervation and maintenance of heart failure medications",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham intervention, maintenance of heart failure medications","SHAM_COMPARATOR","Sham Treatment. After 1 year, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.",[19],"Procedure: Sham procedure and maintenance of heart failure medications",[21,26],{"type":22,"name":23,"description":15,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Sham procedure and maintenance of heart failure medications",[15],null,{"type":22,"name":9,"description":9,"armGroupLabels":27,"otherNames":25},[9],[29],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Xiang Xie","CONTACT","+869914366892","xiangxie999@sina.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"The First Affiliated Hospital of Xinjiang Medical University","RECRUITING","Ürümqi","Xinjiang","830000","China","CN",{"type":44,"coordinates":45},"Point",[46,47],87.60046,43.80096,{"lat":47,"lon":46},[50,53],{"name":51,"role":31,"phone":32,"phoneExt":25,"email":52},"Hai-tao Yang","yht5656@163.com",{"name":54,"role":31,"phone":32,"phoneExt":25,"email":33},"xiang Xie",{"type":56,"investigatorFullName":30,"investigatorTitle":57,"investigatorAffiliation":58,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Head of Hypertension Department, Clinical Professor","First Affiliated Hospital of Xinjiang Medical University",[60],{"name":58,"class":6},"100494247","renal-denervation-in-patients-with-chronic-heart-failure-with-preserved-ejection-fraction-100494247",false,"NCT05715697","Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction","RDN-HFPEF","Inclusion Criteria:\n\n1. signs or symptoms of heart failure;\n2. normal or mildly abnormal systolic LV function (LVEF ≥ 50%);\n3. evidence of diastolic LV dysfunction.\n4. Individual should fulfill the diagnostic WHO criteria for hypertension: SBP \\> 140 mmHg and\u002For DBP \\> 90 mmHg, and is treated with at least 2 antihypertensive drugs. This treatment is expected to be maintained for at least 6 months. Using this regimen the blood pressure should be adequately controlled (\\\u003C 140\u002F90mmHg by 24 hour ambulatory BP measurement).\n5. Individual is adhering to a stable drug regimen HFNEF, with no changes for a minimum of 2 weeks prior to enrollment, and which is expected to be maintained for at least 6 months.\n\nExclusion Criteria:\n\n1. Known secondary cause of hypertension\n2. Anatomy not eligible for renal denervation\n3. Systolic heart failure (LVEF \\\u003C 50%)\n4. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C 30mL\u002Fmin\u002F1.73m2, using the MDRD calculation.\n5. Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and\u002For effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia, significant anaemia, or arrhythmias such as atrial fibrillation).\n6. Individual is pregnant, nursing or planning to be pregnant.","ALL","21 Years","80 Years",{"count":72,"type":73},200,"ESTIMATED","INTERVENTIONAL",[76],"NA","This study aims to explore the potential of RDN as a therapy for HFpEF in a Prospective, Multicenter, Randomized, Blinded, Sham-controlled Study.",[79,80],"Heart Failure With Preserved Ejection Fraction","Renal Denervation","2024-01-30",{"date":83,"type":84},"2024-02-01","ACTUAL",{"date":86,"type":84},"2023-09-01",{"date":88,"type":73},"2026-09-01",{"name":5,"class":6},1]